Syngene International acquires its first US manufacturing facility for USD 50 million, expanding its reach in human and animal health markets.

Biocon arm Syngene International announced today the acquisition of its first biologics facility in the USA from Emergent ...

Syngene International acquires US manufacturing facility, expanding bioreactor capacity and global service capabilities for pharmaceutical innovation.

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading ...

India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent ...

Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will ...

This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...

Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.